Dexchlorpheniramine

RESPIRATORY SYSTEM

Key facts

Dexchlorpheniramine is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1981. DrugCentral lists 18 molecular targets, including HRH1, SLC6A4 and CHRM4. Recorded indications include Allergic conjunctivitis, Allergic rhinitis, Dermatographic urticaria and Itching of skin.

• Approval status: ofp (first approved 1981 by the FDA).
• Molecular targets: HRH1, SLC6A4, CHRM4 and CHRM1 (18 listed in DrugCentral).
• Indications: Allergic conjunctivitis, Allergic rhinitis, Dermatographic urticaria, Itching of skin and Seasonal allergic rhinitis and others.
• ATC code: R06AB02 (Substituted alkylamines).
• Molecular formula: C16H19ClN2; molecular weight 274.79 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (7)

• Allergic conjunctivitis
• Allergic rhinitis
• Dermatographic urticaria
• Itching of skin
• Seasonal allergic rhinitis
• Urticaria
• Vasomotor rhinitis

Contraindications (93)

• Achalasia of esophagus
• Acidosis
• Acute abdominal pain
• Acute exacerbation of asthma
• Acute hepatitis
• Acute pancreatitis
• Alcohol intoxication
• Alcohol withdrawal delirium
• Alcoholism
• Angle-closure glaucoma
• Arterial thrombosis
• Arteriosclerotic vascular disease
• Asthenia
• Atony of colon
• Autonomic dysreflexia
• Benign intracranial hypertension
• Benign prostatic hyperplasia
• Bladder outflow obstruction
• Bleeding
• Bradycardia
• Brain damage
• Breastfeeding (mother)
• Central nervous system depression
• Chronic disease of respiratory system
• Chronic heart failure
• Chronic idiopathic constipation
• Chronic lung disease
• Coma
• Complete trisomy 21 syndrome
• Conduction disorder of the heart
• + 63 more

Mechanism & targets

Molecular targets (18)

Target	Gene	Action	Activity
Histamine H1 receptor	HRH1	antagonist	Ki 9.14
Sodium-dependent serotonin transporter	SLC6A4	unknown	Ki 7.89
Muscarinic acetylcholine receptor M4	CHRM4	unknown	Ki 6.56
Muscarinic acetylcholine receptor M1	CHRM1	unknown	Ki 6.48
Muscarinic acetylcholine receptor M3	CHRM3	unknown	Ki 6.26
Sigma non-opioid intracellular receptor 1	SIGMAR1	unknown	Ki 6.16
Sodium-dependent dopamine transporter	SLC6A3	unknown	Ki 6.13
Muscarinic acetylcholine receptor M5	CHRM5	unknown	Ki 6.13
5-hydroxytryptamine receptor 2A	HTR2A	unknown	Ki 5.98
5-hydroxytryptamine receptor 2C	HTR2C	unknown	Ki 5.92
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 5.68
Muscarinic acetylcholine receptor M2	CHRM2	unknown	Ki 5.60
Sodium-dependent noradrenaline transporter	SLC6A2	unknown	Ki 5.31
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 5.12
Histamine H2 receptor	HRH2	unknown	Ki 5.08
Alpha-1B adrenergic receptor	Adra1b	unknown	Ki 5.07
Membrane-associated progesterone receptor component 1	Pgrmc1	unknown	Ki 4.93
Alpha-1D adrenergic receptor	ADRA1D	unknown	Ki 4.78

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1981-07-14	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
R06AB02	RESPIRATORY SYSTEM › ANTIHISTAMINES FOR SYSTEMIC USE › ANTIHISTAMINES FOR SYSTEMIC USE › Substituted alkylamines
R06AB52	RESPIRATORY SYSTEM › ANTIHISTAMINES FOR SYSTEMIC USE › ANTIHISTAMINES FOR SYSTEMIC USE › Substituted alkylamines

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Cytokine release syndrome	869.5
Erythema	530.4
Febrile neutropenia	421.3
Infusion related reaction	356.3
Anaphylactic shock	295.1
Febrile bone marrow aplasia	279.7
Pyrexia	266.9
Neutropenia	240.9
Rash maculo-papular	191.0
Hypogammaglobulinaemia	189.5
Neutrophil count decreased	177.1
Hepatocellular injury	171.8

Chemical structure

• Molecular formula: C₁₆H₁₉ClN₂
• Molecular weight: 274.79 g/mol
• CAS number: 25523-97-1
• InChIKey: SOYKEARSMXGVTM-HNNXBMFYSA-N
• PubChem CID: 33036

CN(C)CC[C@@H](C1=CC=C(Cl)C=C1)C1=CC=CC=N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Dexchlorpheniramine used for?

DrugCentral lists the following indications for Dexchlorpheniramine: Allergic conjunctivitis, Allergic rhinitis, Dermatographic urticaria, Itching of skin, Seasonal allergic rhinitis, Urticaria and Vasomotor rhinitis.

How does Dexchlorpheniramine work?

Its molecular targets in DrugCentral include HRH1 (antagonist), SLC6A4, CHRM4 and CHRM1.

When was Dexchlorpheniramine first approved?

Dexchlorpheniramine was first approved by the FDA in 1981.

What is the chemical formula of Dexchlorpheniramine?

Dexchlorpheniramine has the molecular formula C16H19ClN2 and a molecular weight of 274.79 g/mol.

Sources

• DrugCentral drug card 4411 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200927 — compound record and bioactivity
• PubChem CID 33036 — chemical identifiers
• DrugBank DB09555 — drug record
• FDA UNII 3Q9Q0B929N — substance identity
• DailyMed: FDA labels for Dexchlorpheniramine — current prescribing information (label search)
• UniProt P35367 (HRH1) — target protein
• UniProt P31645 (SLC6A4) — target protein
• UniProt P08173 (CHRM4) — target protein
• UniProt P11229 (CHRM1) — target protein
• UniProt P20309 (CHRM3) — target protein
• UniProt Q99720 (SIGMAR1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.